Nontumoral portal vein thrombosis in patients awaiting liver transplantation

作者：Chen Hui; Turon Fanny; Hernandez Gea Virginia; Fuster Josep; Garcia Criado Angeles; Barrufet Marta; Darnell Anna; Fondevila Constantino; Carlos Garcia Valdecasas Juan; Carlos Garcia Pagan Juan

来源：Liver Transplantation, 2016, 22(3): 352-365.

DOI：10.1002/lt.24387

Portal vein thrombosis (PVT) occurs in approximately 2%-26% of the patients awaiting liver transplantation (LT) and is no longer an absolute contraindication for LT. Nearly half of PVT cases are accidentally found during the LT procedure. The most important risk factor for PVT development in cirrhosis may be the severity of liver disease and reduced portal blood flow. Whether other inherited or acquired coagulation disorders also play a role is not yet clear. The development of PVT may have no effect on the liver disease progression, especially when it is nonocclusive. PVT may not increase the risk of wait-list mortality, but it is a risk factor for poor early post-LT mortality. Anticoagulation and transjugular intrahepatic portosystemic shunt (TIPS) are 2 major treatment strategies for patients with PVT on the waiting list. The complete recanalization rate after anticoagulation is approximately 40%. The role of TIPS to maintain PV patency for LT as the primary indication has been reported, but the safety and efficacy should be further evaluated. PVT extension and degree may determine the surgical technique to be used during LT. If a conventional end-to-end portal anastomotic technique is used, there is not a major impact on post-LT survival. Post-LT PVT can significantly reduce both graft and patient survival after LT and can preclude future options for re-LT.

• 出版日期2016-3